Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fasting Study
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study was to compare the single-dose oral bioequivalence of Pantoprazole sodium 40 mg
delayed release tablets (containing 45.1 mg of Pantoprazole sodium sesquihydrate equivalent
to 40 mg of Pantoprazole) of OHM Laboratories Inc. USA (a subsidiary of Ranbaxy
Pharmaceuticals Inc. USA) with PROTONIX® 40 mg delayed release tablets (containing 45.1 mg of
Pantoprazole sodium sesquihydrate equivalent to 40 mg of Pantoprazole) of Wyeth
Pharmaceuticals Inc., USA in healthy, adult, human, male subjects under fasting
conditions.condition.